newsfilter
← Latest News
GlobeNewswire·

Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

SLNO
  • Soleno Therapeutics, Inc. appointed Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness who is retiring by the end of Q1 2026.
  • Mr. Mackaness will serve as a consultant to the company through the end of 2026 to ensure a smooth transition.
  • Mrs. Fulk brings over two decades of public company experience, including 15 years at Eli Lilly in roles such as CFO of U.S. Bio-Medicines, VP of Investor Relations, CFO of Lilly Germany, Austria, and Switzerland, and VP of Global Finance and Integration at Elanco.
  • Prior to joining Soleno, Mrs. Fulk served as COO and CFO of 120Water, Inc. from September 2024 to October 2025, and as CFO of Talkspace, Inc. from July 2021 to May 2024.
  • Mrs. Fulk holds a Bachelor of Science in Information Systems and an MBA from Indiana University.
  • CEO Dr. Anish Bhatnagar highlighted Mrs. Fulk's role in supporting the commercial rollout of VYKAT™ XR in the U.S. and pursuing regulatory approval in the EU.
  • VYKAT™ XR (diazoxide choline) extended-release tablets were approved by the FDA on March 26, 2025, for treating hyperphagia in patients aged 4 and older with Prader-Willi syndrome.
  • Dr. Bhatnagar acknowledged Mr. Mackaness's instrumental contributions over the past six-plus years in guiding financial strategy, clinical development, regulatory approval, and the U.S. launch.